To conduct targeted assessments involving vaccine research and surveillance. The current studies range from a meningitis carriage study in Burkina Faso to measure the impact of the MenA vaccine, to rotavirus surveillance in Mozambique to look at vaccine effectiveness.

To expand on an existing program to increase access to comprehensive emergency obstetric care (CEmOC) in Tanzania by integrating family planning (FP), comprehensive post-abortion care (CPAC) and family planning advocacy in ten health centers and add new health centers in Kigoma to be upgraded for the full package of CEmOC, FP and CPAC.

To enable a Pfizer Global Health Fellow to work alongside CDC scientists on assignment in China to improve prevention, detection and control of emerging infectious diseases.

To provide technical assistance, including field support, for the activities of the Surveillance for Enteric Fever in Asia Project and The Coalition Against Typhoid.

To provide evidence about the public health impact and benefits on child health after the introduction of rotavirus vaccine into the Pakistan National Immunization Program system.

To determine feasibility and cost of prevention of Cryptococcal disease in African, Asian and Central American countries via the implementation of a “screen-and-treat” strategy. This strategy will support and guide policy makers in the rollout and sustained management of a successful “screen-and-treat” program. This project is expanding to an additional 8-12 countries.

To offer early warnings of emerging biological, chemical, radiological and nuclear incidents, and to relay critical information to decision makers.

To help CDC serve as a Global Reference Laboratory for the rotavirus and the invasive bacterial vaccine preventable diseases (IBVPD) laboratory networks, which provide support to the WHO-coordinated global rotavirus and the global IBVPD surveillance networks.

To maintain, produce, authenticate and distribute arthropod vectors and associated reagents for the Microbiology and Infectious Diseases Biological Research Resources (MID-BRR) Program.

To conduct an evaluation of N. Meningitidis and N. Lactamica in Burkina Faso as part of a larger initiative to introduce a novel serogroup A conjugate meningococcal vaccine in Africa and eliminate epidemic meningitis.